NYU Stern CSB Valuation Tool Case Study

Engaging with Private Equity GPs



Kohlberg & Co. Case Study - Due Diligence Assessment

Kohlberg used the Value Creation Tool to help link diligence findings with post-acquisition strategy development, using a recently closed deal in the **Healthcare** sector to evaluate the process.







AuMs ~\$14B





26 PCs

Sub-Sector: Biotechnology & Pharmaceutical

HQ: U.S. # of Employees: ~3,500


Current Status Score

Suyout 0 0				
Material Issues	Value Drivers	Company Practices at Acquisition	(1 = not well managed, 5 = very well managed)	
Labor Practices	Improved retention, higher productivity, lower recruitment costs	The company maintains robust engagement initiatives such as exit/stay interviews, engagement surveys, and professional development programs. Benefits and policies are governed by a global employee handbook, which is inclusive of location-specific addendums.		
Business Ethics	Reduced regulatory, reputational or market risk	The company's operations comply with extensive regulations and are subject to regular audits by regulatory bodies and industry organizations. A cross-functional committee oversees the ethics and compliance program, with annual ethics training provided to all employees.		
Product Quality & Safety	Reduced customer loss, improved patient recruitment, and lower risk of lawsuits or regulatory fines	The company has robust management practices including SOPs, personnel trainings, impact assessments, an internal regulatory intelligence newsletter, and an anonymous incident reporting mechanism for patients/participants.		
Employee Health & Safety	Increased productivity and retention, reduced workplace insurance costs and better ability to hire the best talent	The company has a robust health and safety manual, provides extensive training on safety topics and conducts regular safety audits. While it has fewer severe incidents than industry, frequency of minor incidents is higher.		
Physical Impacts of Climate Change	Reduced likelihood of operational disruptions and associated costs	The company maintains site-specific business continuity plans.		
GHG Emissions	Improved operational efficiency, reduced exposure to regulatory fines, lower cost of capital, better customer retention	The company estimates Scope 1 & 2 emissions and has implemented site-level energy efficiency initiatives. However, it lacks short and long-term targets and a corporate climate strategy.		



Issue Prioritization

Following the diligence assessment, each material issue was assessed for downside risk and upside opportunity. Strategy development



Based on these findings, Kohlberg developed an ESG strategy focused on <u>mitigating climate-related downside risks</u> and <u>capitalizing on climate-related upside opportunities</u>, following the ROSI framework, on the following page.



ROSI and ESG Strategy Development

ROSI Steps	Kohlberg Process	What we did	What we found	
1. Assess Opportunity and Risk	Pre-acquisition Diligence	The target company underwent diligence on various material issues, with findings entered into the ROSI diligence tool and scored based on current practices.	GHG emissions and managing climate risks were not on the company's radar or recognized as key focus areas at the time of acquisition.	
2. Identify Associated Strategy(ies)	Baseline Assessment	Conducted an assessment of peer performance, customer and regulatory requirements (e.g., CSRD), mapping them to the upside and downside categories based on the CSB issue prioritization framework.	Downside Risk: The company was exposed to climate disclosure regulation in the EU Upside Opportunity: As part of its growth strategy, the company was focused on winning new contracts with pharma companies with public net zero targets	
3. Determine Expected Benefits		Referenced ROSI Strategy & KPI database to determine key mediating factors and associated benefits.	 ROSI Mediating Factor 1: Risk Management ROSI Mediating Factor 2: Stakeholder Engagement/Customer Loyalty 	
4. Quantify Results of Benefits	Strategy Development	 Developed a business case for formalizing ESG and climate program Created implementation strategy based on findings from baseline assessment 	 Top pharma customers are prioritizing vendors based on sustainability performance and climate program maturity (impacting the top line), while costs related to 	
		Obtained management buy-inSet near term goals	regulatory noncompliance affect the bottom line.	
	Strategy Execution	What we plan to do	Value creation rationale	
5. Monetize the Benefits		 Annual Scopes 1, 2 and 3 Develop a decarbonization roadmap, focused on initiatives with highest ROI Achieve accreditation for ESG and climate improvements by aligning with customer requirements such as enhancing 	 Avoidance of regulatory penalties for non-compliance Identify customers with climate and ESG requirements, then focus on revenue expansion and retention through targeted engagement Track savings from increased efficiency and lower 	
	Exit	third-party assessments (e.g., EcoVadis, SBTi) • Leverage ESG/ climate program as a competitive advantage	energy costs as the decarbonization plan is implemented Incorporate the above into exit materials	



Thank You

BSR™ is a global nonprofit organization that works with its network of more than 300 member companies and other partners to build a just and sustainable world. From its offices in Asia, Europe, and North America, BSR™ develops sustainable business strategies and solutions through consulting, research, and cross-sector collaboration.

www.bsr.org













BSR Disclaimer

The conclusions presented in this document represent BSR's best professional judgment, based upon the information available and conditions existing as of the date of the review. In performing its assignment, BSR relies upon publicly available information, information provided by the PE Firms engaged, and information provided by third parties. Accordingly, the conclusions in this document are valid only to the extent that the information provided or available to BSR was accurate and complete, and the strength and accuracy of the conclusions may be impacted by facts, data, and context to which BSR was not privy. As such, the facts or conclusions referenced in this document should not be considered an audit, certification, or any form of qualification. This document does not constitute and cannot be relied upon as legal or investment advice of any sort and cannot be considered an exhaustive review of legal, investment, or regulatory compliance. BSR makes no representations or warranties, express or implied, about the business or its operations. BSR maintains a policy of not acting as a representative of its membership, nor does it endorse specific policies or standards. The views expressed in this document do not reflect those of BSR member companies.

